BioLineRx Ltd.
BLRX
$3.39
$0.020.56%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -7.90M | -1.18M | -2.98M | -7.82M | -3.40M |
| Total Depreciation and Amortization | 364.00K | 441.00K | 2.24M | 2.96M | 3.26M |
| Total Amortization of Deferred Charges | 82.00K | 784.00K | 802.00K | 802.00K | 1.44M |
| Total Other Non-Cash Items | -2.59M | -9.38M | -14.32M | -14.66M | -22.10M |
| Change in Net Operating Assets | 2.29M | 1.26M | 770.00K | -2.49M | -11.56M |
| Cash from Operations | -7.76M | -8.07M | -13.48M | -21.20M | -32.36M |
| Capital Expenditure | -31.00K | -25.00K | 6.00K | 6.00K | -21.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 0.00 | 11.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.37M | -8.52M | 2.94M | 9.43M | 4.53M |
| Cash from Investing | 2.34M | -8.55M | 2.95M | 9.45M | 4.51M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 19.22M |
| Total Debt Repaid | -4.94M | -5.01M | -15.86M | -15.64M | -15.30M |
| Issuance of Common Stock | 3.20M | 13.89M | 24.89M | 24.55M | 27.26M |
| Repurchase of Common Stock | -- | -- | -- | -180.00K | -180.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.75M | 8.88M | 9.03M | 8.73M | 31.00M |
| Foreign Exchange rate Adjustments | 642.00K | 549.00K | 586.00K | 593.00K | -111.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.53M | -7.19M | -922.00K | -2.43M | 3.05M |